ZA202203520B - [1,4]oxazepino[2,3-c]quinolinone derivatives as bcl6 inhibitors - Google Patents
[1,4]oxazepino[2,3-c]quinolinone derivatives as bcl6 inhibitorsInfo
- Publication number
- ZA202203520B ZA202203520B ZA2022/03520A ZA202203520A ZA202203520B ZA 202203520 B ZA202203520 B ZA 202203520B ZA 2022/03520 A ZA2022/03520 A ZA 2022/03520A ZA 202203520 A ZA202203520 A ZA 202203520A ZA 202203520 B ZA202203520 B ZA 202203520B
- Authority
- ZA
- South Africa
- Prior art keywords
- oxazepino
- bcl6
- quinolinone derivatives
- inhibitors
- bcl6 inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201914860A GB201914860D0 (en) | 2019-10-14 | 2019-10-14 | Inhibitor compounds |
| PCT/GB2020/052588 WO2021074620A1 (en) | 2019-10-14 | 2020-10-14 | [1,4]oxazepino[2,3-c]qui noli none derivatives as blc6 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202203520B true ZA202203520B (en) | 2025-09-25 |
Family
ID=68619494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2022/03520A ZA202203520B (en) | 2019-10-14 | 2022-03-25 | [1,4]oxazepino[2,3-c]quinolinone derivatives as bcl6 inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12528826B2 (enExample) |
| EP (1) | EP4045510B1 (enExample) |
| JP (1) | JP7668273B2 (enExample) |
| KR (1) | KR20220083761A (enExample) |
| CN (1) | CN114650995A (enExample) |
| AU (1) | AU2020365518B2 (enExample) |
| CA (1) | CA3157716A1 (enExample) |
| ES (1) | ES3047908T3 (enExample) |
| GB (1) | GB201914860D0 (enExample) |
| IL (1) | IL292182B1 (enExample) |
| MX (1) | MX2022004419A (enExample) |
| WO (1) | WO2021074620A1 (enExample) |
| ZA (1) | ZA202203520B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3095371A1 (en) | 2018-04-13 | 2019-10-17 | Cancer Research Technology Limited | Bcl6 inhibitors |
| GB201914860D0 (en) | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
| CA3154386A1 (en) | 2019-10-17 | 2021-04-22 | Michael Berlin | Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety |
| KR20230171979A (ko) | 2021-04-16 | 2023-12-21 | 아비나스 오퍼레이션스, 인코포레이티드 | Bcl6 단백질 분해의 조절제 및 관련 사용 방법 |
| PE20250756A1 (es) | 2022-06-06 | 2025-03-13 | Treeline Biosciences Inc | Degradadores bifuncionales de bcl6 de quinolona triciclica |
| EP4536649A1 (en) | 2022-06-13 | 2025-04-16 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
| KR20250023481A (ko) | 2022-06-13 | 2025-02-18 | 트리라인 바이오사이언시스, 인크. | 1,8-나프티리딘-2-온 이종이작용성 bcl6 분해제 |
| KR20240161027A (ko) * | 2023-05-03 | 2024-11-12 | 인제대학교 산학협력단 | BTK 분해제 및 Bcl-6 분해제를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| AU2024331309A1 (en) * | 2023-09-01 | 2026-03-19 | Treeline Biosciences, Inc. | Tricyclic quinolone bcl6 bifunctional degraders |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0259572A (ja) | 1988-08-23 | 1990-02-28 | Mitsubishi Kasei Corp | ベンズイミダゾロン誘導体又はその塩類 |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DE69720965T2 (de) | 1996-02-13 | 2004-02-05 | Astrazeneca Ab | Chinazolinderivate und deren verwendung als vegf hemmer |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| CA2349616A1 (en) | 1998-12-04 | 2000-06-15 | Neurosearch A/S | New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| PT1154774E (pt) | 1999-02-10 | 2005-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de angiogenese |
| IL147309A0 (en) | 1999-07-21 | 2002-08-14 | Fujisawa Pharmaceutical Co | Benzimidazolone derivatives and pharmaceutical compositions containg the same |
| AU2001258628A1 (en) | 2000-05-31 | 2001-12-11 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| WO2001094311A1 (en) | 2000-06-08 | 2001-12-13 | Mitsubishi Pharma Corporation | Cytoprotectors |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
| UY27304A1 (es) | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
| WO2003095448A1 (en) | 2002-05-06 | 2003-11-20 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
| US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
| US20050256157A1 (en) | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
| WO2008011032A1 (en) | 2006-07-17 | 2008-01-24 | Amgen Inc. | Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors |
| WO2008066887A2 (en) | 2006-11-30 | 2008-06-05 | Albert Einstein College Of Medicine Of Yeshiva University | Small molecule inhibitors of bcl6 |
| US8686008B2 (en) | 2007-08-16 | 2014-04-01 | The University Of Mississippi | Highly selective sigma receptor ligands |
| WO2009063240A1 (en) | 2007-11-16 | 2009-05-22 | Arrow Therapeutics Limited | 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase |
| SG187502A1 (en) | 2008-02-01 | 2013-02-28 | Takeda Pharmaceutical | Oxim derivatives as hsp90 inhibitors |
| AU2009314760B2 (en) | 2008-11-11 | 2011-11-10 | Je Il Pharmaceutical Co.,Ltd | Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same |
| BRPI1006942A2 (pt) | 2009-01-23 | 2016-04-12 | Rigel Pharmaceuticals Inc | composto, composição farmacêutica, kit, métodos para inibir uma atividade de uma jak quinase, para tratar uma doença, para tratar a rejeição de transplante de aloenxerto em um receptor de transplante, para tratar uma reação de hipersensibilidade, e para inibir uma cascata de transdução de sinal, e, uso do composto |
| KR20120114355A (ko) | 2010-01-13 | 2012-10-16 | 글락소스미스클라인 엘엘씨 | 화합물 및 방법 |
| CA2840883C (en) | 2011-07-07 | 2019-07-16 | Merck Patent Gmbh | Substituted azaheterocycles |
| CA2877146C (en) | 2012-06-18 | 2020-10-20 | Dart Neuroscience (Cayman) Ltd | Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds |
| EP2964642B1 (en) | 2013-03-05 | 2017-11-15 | F. Hoffmann-La Roche AG | Inhibitors of bruton's tyrosine kinase |
| US9943506B2 (en) | 2013-06-17 | 2018-04-17 | Cornell University | BCL6 inhibitors as anticancer agents |
| CN105017159B (zh) | 2014-04-28 | 2019-05-17 | 四川大学 | 5-氟-2,4-二取代氨基嘧啶衍生物及其制备方法和用途 |
| US10266549B2 (en) | 2014-08-25 | 2019-04-23 | Salk Institute For Biological Studies | ULK1 inhibitors and methods using same |
| US20160060260A1 (en) | 2014-08-29 | 2016-03-03 | Board Of Regents, The University Of Texas System | Bromodomain inhibitors for treating disease |
| HK1244427A1 (zh) | 2014-12-06 | 2018-08-10 | Intra-Cellular Therapies, Inc. | 有机化合物 |
| WO2017007658A1 (en) | 2015-07-07 | 2017-01-12 | Rigel Pharmaceuticals, Inc. | A combination for immune mediated cancer treatment |
| US11001570B2 (en) * | 2016-12-13 | 2021-05-11 | Boehringer Ingelheim International Gmbh | 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors |
| US11161839B2 (en) | 2017-05-26 | 2021-11-02 | The Institute Of Cancer Research: Royal Cancer Hospital | 2-quinolone derived inhibitors of BCL6 |
| JP7202315B2 (ja) | 2017-05-26 | 2023-01-11 | キャンサー・リサーチ・テクノロジー・リミテッド | ベンズイミダゾロン由来のｂｃｌ６阻害剤 |
| CA3095371A1 (en) | 2018-04-13 | 2019-10-17 | Cancer Research Technology Limited | Bcl6 inhibitors |
| GB201819136D0 (en) | 2018-11-23 | 2019-01-09 | Cancer Research Tech Ltd | Inhibitor compounds |
| GB201914860D0 (en) | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
-
2019
- 2019-10-14 GB GB201914860A patent/GB201914860D0/en not_active Ceased
-
2020
- 2020-10-13 IL IL292182A patent/IL292182B1/en unknown
- 2020-10-14 US US17/768,174 patent/US12528826B2/en active Active
- 2020-10-14 AU AU2020365518A patent/AU2020365518B2/en active Active
- 2020-10-14 KR KR1020227016037A patent/KR20220083761A/ko active Pending
- 2020-10-14 JP JP2022522065A patent/JP7668273B2/ja active Active
- 2020-10-14 WO PCT/GB2020/052588 patent/WO2021074620A1/en not_active Ceased
- 2020-10-14 CA CA3157716A patent/CA3157716A1/en active Pending
- 2020-10-14 CN CN202080072281.5A patent/CN114650995A/zh active Pending
- 2020-10-14 MX MX2022004419A patent/MX2022004419A/es unknown
- 2020-10-14 ES ES20793780T patent/ES3047908T3/es active Active
- 2020-10-14 EP EP20793780.6A patent/EP4045510B1/en active Active
-
2022
- 2022-03-25 ZA ZA2022/03520A patent/ZA202203520B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020365518B2 (en) | 2026-04-23 |
| JP2022551950A (ja) | 2022-12-14 |
| EP4045510A1 (en) | 2022-08-24 |
| IL292182A (en) | 2022-06-01 |
| KR20220083761A (ko) | 2022-06-20 |
| WO2021074620A1 (en) | 2021-04-22 |
| EP4045510C0 (en) | 2025-07-30 |
| WO2021074620A9 (en) | 2021-06-17 |
| MX2022004419A (es) | 2022-08-08 |
| US12528826B2 (en) | 2026-01-20 |
| CN114650995A (zh) | 2022-06-21 |
| GB201914860D0 (en) | 2019-11-27 |
| AU2020365518A1 (en) | 2022-04-14 |
| ES3047908T3 (en) | 2025-12-05 |
| EP4045510B1 (en) | 2025-07-30 |
| IL292182B1 (en) | 2026-02-01 |
| US20240217987A1 (en) | 2024-07-04 |
| JP7668273B2 (ja) | 2025-04-24 |
| CA3157716A1 (en) | 2021-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202203520B (en) | [1,4]oxazepino[2,3-c]quinolinone derivatives as bcl6 inhibitors | |
| MX2023005636A (es) | Inhibidores de bcl6 derivados de bencimidazolona. | |
| EP4371562A3 (en) | 2-quinolone derived inhibitors of bcl6 | |
| MX2020010805A (es) | Inhibidores de bcl6. | |
| PH12022552739A1 (en) | Fused tricyclic kras inhibitors | |
| GEAP202416515A (en) | Quinoline compounds as inhibitors of kras | |
| MX2022013223A (es) | [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2. | |
| CR20240059A (es) | Compuestos tricíclicos como inhibidores de kras. | |
| MX2021013110A (es) | Compuestos heterociclicos como inhibidores de la cinasa ret. | |
| GEAP202616866A (en) | 2-azabicyclo[2.2.1]heptane kras inhibitors | |
| NZ795548A (en) | Allosteric egfr inhibitors and methods of use thereof | |
| MX2023012981A (es) | Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos. | |
| EP4420728A3 (en) | Novel chroman derivatives having estrogen receptor degradation activity and uses thereof | |
| CR20210544A (es) | DERIVADOS DE 1,1-DIÓXIDO DE 3-AMINO-4H-BENZO[E][1,2,4] tiadiazina COMO INHIBIDORES DE MRGX2 | |
| EP3722296A3 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| MX2021008667A (es) | Derivado de pirrolopirimidina y composición farmacéutica para prevenir o tratar enfermedades relacionadas con la proteína quinasa que comprende el mismo como principio activo. | |
| MX2020010568A (es) | Derivados de urea ciclica fusionada como antagonista de crhr2. | |
| PH12022550843A1 (en) | Thienopyrimidones as trpa1 inhibitors | |
| JOP20220107A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها | |
| MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
| PH12019501642A1 (en) | Novel compounds and their use in the treatment of schistosomiasis | |
| PH12022550846A1 (en) | Thienopyrimidones as trpa1 inhibitors | |
| MX2021015898A (es) | Compuestos heterocíclicos bicíclicos como inhibidores de actividad de ofbcdin3d. | |
| PH12021550143A1 (en) | Pyridopyrimidines as histamine h4-receptor inhibitors | |
| MX2021003901A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. |